Real-life comparison of three intravitreal antibiotic drug regimens in endophthalmitis.
Ceftazidime
endophthalmitis
imipenem
piperacillin/tazobactam
vancomycin
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
entrez:
3
5
2022
pubmed:
4
5
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
Real-life comparison of three intravitreal drug regimens used in cases of endophthalmitis at a tertiary care center in India. In this prospective, comparative study, patients of bacterial endophthalmitis were grouped according to intravitreal antibiotic drug regimens into Group 1 (ceftazidime and vancomycin), Group 2 (piperacillin + tazobactam and vancomycin), and Group 3 (imipenem and vancomycin). Forty-eight hours after injection nonresponding/worsening patients underwent vitrectomy. Vitreous samples were subjected to microbiological and pharmacokinetic tests. A total of 64 patients were included and divided into Group 1: 29, Group 2: 20, and Group 3: 15 cases. Also, 75% of patients were post-surgical endophthalmitis, whereas 25% were post-traumatic. Improvement in vision (V The choice of antibiotics did not affect the rate of vitrectomy and final vision in a real-life scenario. Ceftazidime and vancomycin can still be used as first-line intravitreal antibiotics owing to their comparable microbial sensitivity profile and adequate ocular bioavailability.
Identifiants
pubmed: 35502054
pii: IndianJOphthalmol_2022_70_5_1696_343985
doi: 10.4103/ijo.IJO_2640_21
pmc: PMC9333035
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Ceftazidime
9M416Z9QNR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1696-1700Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Déclaration de conflit d'intérêts
None
Références
Ophthalmology. 1997 Feb;104(2):261-72
pubmed: 9052630
Lancet Infect Dis. 2018 Jan;18(1):108-120
pubmed: 29102324
Am J Clin Pathol. 1966 Apr;45(4):493-6
pubmed: 5325707
J Antimicrob Chemother. 2012 Dec;67(12):2793-803
pubmed: 22915465
Ther Adv Infect Dis. 2016 Feb;3(1):15-21
pubmed: 26862399
Case Rep Ophthalmol. 2016 Feb 20;7(1):103-7
pubmed: 27293409
Drugs. 1987 Mar;33(3):183-241
pubmed: 3552595
Indian J Ophthalmol. 2020 Apr;68(4):627-631
pubmed: 32174583
Saudi J Ophthalmol. 2012 Apr;26(2):181-9
pubmed: 23960990
Am J Ophthalmol. 1986 Mar 15;101(3):332-41
pubmed: 3485382
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17165-70
pubmed: 21969582
Ophthalmology. 1985 Apr;92(4):467-71
pubmed: 4000641
J Ophthalmol. 2015;2015:261310
pubmed: 25802752
Graefes Arch Clin Exp Ophthalmol. 2003 Jun;241(6):478-83
pubmed: 12756578
Am J Ophthalmol. 2010 Mar;149(3):482-7.e1-2
pubmed: 20053391
Am J Ophthalmol Case Rep. 2018 Feb 28;10:211-214
pubmed: 29552670
Clin Exp Ophthalmol. 2017 Apr;45(3):254-260
pubmed: 27616274
Br J Ophthalmol. 1997 Nov;81(11):1006-15
pubmed: 9505828